Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tegavivint with Gemcitabine in Relapsed or Refractory Osteosarcoma
NCT07144254Phase 1Recruiting
- Sponsor
- Emory University
- Start
- Jan 2026
- Primary completion
- May 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of tegavivint in osteosarcoma (OS), sponsored by Emory University. Primary endpoint: Maximum Tolerated Dose at 21 days. Started Jan 2026; status: recruiting.
02
Drugs
tegavivint
03
Conditions
osteosarcoma (OS)
Beyond the preview
Go deeper on NCT07144254.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07144254.